- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.10. | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | ||
| 17.10. | Astellas walks away from gene therapy pact with Taysha before pivotal trial launch | ||
| 17.10. | I-Mab undergoes makeover, with new name, strategy, asset and Hong Kong IPO plans | ||
| 17.10. | ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial | ||
| 17.10. | Unpacking the FDA transparency push on CRLs | ||
| 17.10. | Kezar plans layoffs after FDA cancels meeting to discuss next trial | ||
| 17.10. | FDA names nine first recipients of 1-to-2 month priority review vouchers | ||
| 16.10. | Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T deal | ||
| 16.10. | Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaring | ||
| 16.10. | French antibody biotech draws in $122M for end-of-year clinical push | ||
| 16.10. | Dianthus offers up to $1B for China biotech's autoimmune 'pipeline in a product' | ||
| 16.10. | Sanofi inks $500M deal with Evoq for next-gen autoimmune tech | ||
| 16.10. | AstraZeneca pens fresh IBD collab with long-term AI partner Immunai worth $85M | ||
| 15.10. | Boehringer Ingelheim digs in on ADCs, offering up to $991M to license cancer prospect from Korea's AimedBio | ||
| 15.10. | Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins | ||
| 15.10. | Novo Nordisk pens $2.1B deal for Omeros' stalled PNH drug | ||
| 14.10. | Lila Sciences adds Nvidia-backed $115M to series A, bringing total haul to $350M | ||
| 14.10. | BioCryst inks $700M Astria buyout to challenge Takeda for rare disease market | ||
| 14.10. | Kailera taps Bain-led syndicate for $600M to carry Zepbound challenger into phase 3 | ||
| 14.10. | Denali's Hunter syndrome drug latest to be hit by FDA decision delay | ||
| 13.10. | 'Not here to refine the status quo': Excellergy emerges with $70M, plans to redefine allergy therapeutics | ||
| 13.10. | Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates | ||
| 13.10. | Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohort | ||
| 13.10. | Moderna posts melanoma data behind decision to say 'I do' to IDO | ||
| 10.10. | Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .